*In Q2 2020, OncoCube was founded by Erden Banoglu, Özgür Şahin, and Burcu Çalışkan to advance TACC3 inhibitors developed by the founders. Subsequently, OncoCube entered into a sponsored collaborative research agreement with A2A Pharmaceuticals to further the development of this program. This collaboration later evolved into the granting of worldwide exclusive rights to A2A Pharmaceuticals to develop, commercialize, and sublicense TACC3 inhibitors, including AO-252, a first-in-class oral TACC3 inhibitor that received IND clearance in 2023. AO-252 is currently being evaluated in a Phase I clinical trial (NCT06136884) led by A2A Pharmaceuticals and has already demonstrated significant efficacy with a wide therapeutic window.